Haloperidol Injection - Approved for Marketing
On October 21, 2025, our company's haloperidol injection was approved for marketing. The product was approved according to the new registration classification of chemical drugs and deemed to have passed the consistency evaluation. This drug belongs to the national basic medicine and Class A medical insurance drugs.
Haloperidol is a classic antipsychotic drug belonging to the butyrylbenzenes class. It mainly works by blocking dopamine receptors and has strong antipsychotic effects. The indications are for use in acute and chronic types of schizophrenia and mania. Intramuscular injection of this product can quickly control excitement, agitation, hostile emotions, and aggressive behavior. It can also be used for organic mental disorders and geriatric mental disorders.